The Role of Growth Factors in Autocrine Loops

Growth factors are the molecular bridges between external environmental cues and intracellular signaling that controls cell division, survival, differentiation, and migration. When a cell produces a growth factor for which it also expresses a functional receptor, an autocrine loop is established. This situation arises transiently in normal physiology for amplification and maintenance purposes, and permanently (and pathologically) in cancer and fibrotic disease.

EGF Family: The Prototypic Autocrine Ligands

The EGF family comprises 13 ligands that activate four receptor tyrosine kinases (EGFR/HER1, HER2, HER3, HER4). EGF family ligands are synthesized as transmembrane precursors; their mature forms are released by ADAM family metalloproteinase sheddases (primarily ADAM10 and ADAM17). Sheddase activity is regulated by cellular signals including mechanical stress, inflammatory mediators, and GPCR activation, meaning that EGF family autocrine loops are subject to dynamic regulation by the cellular and tissue environment.

In wound healing, keratinocytes at wound edges shed EGF family ligands including HB-EGF (heparin-binding EGF) and TGF-alpha, initiating autocrine EGFR stimulation that drives the proliferative and migratory responses required for wound closure. This physiological role becomes a liability in cancer: squamous cell carcinomas frequently co-express TGF-alpha and EGFR, with the autocrine EGFR loop driving uncontrolled proliferation.

PDGF and Stromal Cell Autocrine Loops

Platelet-derived growth factor (PDGF), which signals through PDGFR-alpha and PDGFR-beta, forms important autocrine loops in mesenchymal cell types. Glioblastoma cells frequently co-express PDGF and its receptors, creating a PDGF autocrine loop that is a validated therapeutic target (imatinib, sunitinib). Cancer-associated fibroblasts (CAFs) produce PDGF that can act in autocrine fashion, contributing to their own activated myofibroblast-like phenotype and the desmoplastic tumor microenvironment. For therapeutic strategies to interrupt these loops, see our article on targeting autocrine pathways in drug development.

For more information, visit our homepage or our resources section.